Sickle Cell Matters
Posted: September 10, 2021
It’s Not Just Support. It’s Solutions.
September is National Sickle Cell Awareness Month, a time to acknowledge and educate how this often-invisible and rare disease impacts over 100,000 people in the U.S., most of whom are of African descent. Treatment can include antibiotics, pain management, intravenous fluids, blood transfusion and surgery.
Sickle Cell Disease Association of America (SCDAA) theme for 2021 is Sickle Cell Matters. DiaPharma celebrates the Scientists and Medical Professionals helping to advance knowledge, awareness, and treatment options for Sickle Cell Disease.
Tools for Sickle Cell Disease Research
From HbS flow cytometry antibodies, coagulation kits and biomarker assays to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell Research.
Anti-Hemoglobin S antibodies from DiaPharma for flow cytometry applications
|Anti-HbS FITC||57-8||Anti-Hemoglobin S antibody conjugated with fluorochrome FITC||IQP-574F|
|Anti-HbF1 Dy-410||WBAC HbF1||Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-410||IQP-567D|
|Anti-HbF1 FITC||WBAC HbF1||Anti-Hemoglobin F antibody conjugated with fluorochrome FITC||IQP-567F|
|Anti-HbF1 R-PE||WBAC HbF1||Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE||IQP-567R|
|Anti-panHb APC||PHB1||Anti-pan Hemoglobin antibody conjugated with fluorochrome APC||IAP-585A|
Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established.
Coagulation Markers in Research
It is suggested that aberrant coagulation and platelet overactivation contribute to the pathogenesis of SCD. Further research and clinical trials are needed to explore the mechanisms driving abnormal coagulation in SCD and to identify effective therapies to treat it. DiaPharma offers a range of assays to further SCD research:
|Coagulation Factors||Components||Function||Biomarkers and Methods of Evaluation||Activity in Sickle Cell Disease|
|Extrinsic Pathway||Tissue factor (TF) FVII||Primary pathway to initiate coagulation following vascular endothelial injury||Prothrombin time (PT)||Increased TF expression|
|Intrinsic Pathway||Prekallikrein HMWK, FXII, FXI||Activated by exposed collagen in the subendothelium and functions to initiate clot formation||Activated partial thromboplastin time (aPTT)||Decreased Prekallikrein, FXII, and HMWK plasma levels
Increased levels of procoagulant microparticles
|Common Pathway||FV, FVIII, FIX, FX thrombin
|Catalysts in the final steps of coagulation to cleave fibrinogen and form blood clots||Thrombin Generation Assays (TGA), TAT, PAP, F1.2, D-dimers, fibrinogen||Increased thrombin levels|
|Fibrinolysis||Plasmin||Enzymatic degradation of fibrin in blood clots||uPA, tPA, PAI-1, D-dimers||Increased fibrinolytic activity|
|Platelets activate and aggregate to form a platelet plug||vWF, ADAMTS-13, Platelet Function Tests||Increased platelet numbers, platelet activation, and platelet aggregation|
|Activated by the coagulation system and contributes to thrombus formation||C3a and C5a||Increased C3a and C5a expression|
|Anticoagulation Proteins||Protein C
|Negative feedback to regulate coagulation and inflammation||Protein C
|Decreased Protein C and Protein S levels|
Automated Measurement of Primary and Secondary Hemostasis Markers
|Instrument||Fully Automated Coagulation Analyzer||Clot Growth & Fibrinolysis Dynamics||Primary Hemostasis and Platelet Function Testing|
|Ceveron® 100 Series||Thrombodynamics||T-TAS® 01||Atlas PST|
Ceveron® series, Thrombodynamics®, and Atlas® PST are for research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846